FGF and Stress Regulate CREB and ATF-1 Via a Pathway Involving P38 MAP Kinase and MAPKAP Kinase-2
Overview
Molecular Biology
Affiliations
Fibroblast growth factor (FGF) activates a protein kinase cascade in SK-N-MC cells that regulates gene expression at a cyclic-AMP response element (CRE) by stimulating the transcriptional activity of CREB. The activation of CREB is prevented by a dominant negative mutant of Ras and triggered via the same site (Ser133) that becomes phosphorylated in response to cyclic AMP and Ca2+. However, the effect of FGF is not mediated by cyclic AMP-dependent protein kinase, TPA-sensitive isoforms of protein kinase-C, p70S6K or p90rsk (all of which phosphorylate CREB at Ser133 in vitro). Instead, we identify the FGF-stimulated CREB kinase as MAP kinase-activated protein (MAPKAP) kinase-2, an enzyme that lies immediately downstream of p38 MAP kinase, in a pathway that is also stimulated by cellular stresses. We show that MAPKAP kinase-2 phosphorylates CREB at Ser133 in vitro, that the FGF- or stress-induced activation of MAPKAP kinase-2 and phosphorylation of CREB and ATF-1 are prevented by similar concentrations of the specific p38 MAP kinase inhibitor SB 203580, and that MAPKAP kinase-2 is the only detectable SB 203580-sensitive CREB kinase in SK-N-MC cell extracts. We also show that transfection of RK/p38 MAP kinase in SK-N-MC cells, but not transfection of p44 MAP kinase, activates Gal4-CREB-dependent transcription via Ser133. These findings identify a new growth factor and stress-activated signaling pathway that regulates gene expression at the CRE.
The impact of signaling pathways on the desmosome ultrastructure in pemphigus.
Schmitt T, Huber J, Pircher J, Schmidt E, Waschke J Front Immunol. 2025; 15:1497241.
PMID: 39882246 PMC: 11774707. DOI: 10.3389/fimmu.2024.1497241.
Unveiling signaling pathways inducing MHC class II expression in neutrophils.
Forrer P, Palianina D, Stuhler C, Kreuzaler M, Roux J, Li J Front Immunol. 2024; 15:1444558.
PMID: 39403371 PMC: 11472776. DOI: 10.3389/fimmu.2024.1444558.
Li L, Lai X, Ni Y, Chen S, Qu Y, Hu Z J Physiol Sci. 2024; 74(1):8.
PMID: 38331728 PMC: 10851531. DOI: 10.1186/s12576-024-00902-x.
Potential roles of FGF5 as a candidate therapeutic target in prostate cancer.
Stangis M, Colah A, McLean D, Halberg R, Collier L, Ricke W Am J Clin Exp Urol. 2023; 11(6):452-466.
PMID: 38148937 PMC: 10749387.
Li Y, Patterson M, Morgan E, Wasson C, Ryder E, Barba-Moreno D J Med Virol. 2023; 95(8):e29025.
PMID: 37565725 PMC: 10952218. DOI: 10.1002/jmv.29025.